CardioComm Solutions Inc. Enters Into Equipment Purchase Agreement with AstraZeneca Canada Inc.
Published: Nov 29, 2011
Etienne Grima, CEO of CardioComm Solutions, stated, “This is our first direct agreement with a leading Canadian pharmaceutical company. As part of this agreement, CardioComm will coordinate and manage a web-based, virtual Holter recording collection service through our existing C4 (CardioComm Coordinating Centre) service. Recordings uploaded through various clinical trial sites will be collected, validated and then provided for analysis.”
The study’s Holter equipment was specifically selected from NorthEast Monitoring, Inc. (NEMon). Scott Winick, Director, Sales and Marketing for NEMon, stated, “We’ve been collaborating with CardioComm Solutions for several years on a variety of projects, but this is the largest thus far. We feel that CardioComm has a much wider vision as a provider of cardiac services than most. With their input, we have developed a virtual Holter system that CardioComm Solutions will deploy via their C4 Service. We’re pleased to provide our technology to and collaborate with visionary partners like CardioComm, and look forward to developing an even closer relationship in the future.”
For more information on any CardioComm product or service, call 1-877-977-9425 toll free in the U.S. and Canada, or email firstname.lastname@example.org.
About CardioComm Solutions, Inc.
CardioComm’s patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices.
CardioComm Solutions, Inc. is headquartered in Toronto, Canada, with offices in Victoria, B.C.
AstraZeneca is committed to the research, development and manufacturing of valuable prescription medicines. We have an extensive product portfolio spanning six therapeutic areas: gastrointestinal, cardiovascular, infection, neuroscience, oncology and respiratory.
AstraZeneca’s Canadian headquarters are located in Mississauga, Ontario, and a state-of-the-art drug discovery centre is based in Montreal, Quebec.
For more information, please visit the company’s website at www.astrazeneca.ca.
PRowrite Public Relations
Christel K. Hall, APR CBC
Etienne Grima, M.Sc. CHE